key: cord-0938946-ik7qh2kl
authors: Wong, Aaron K.; Wawryk, Olivia; Sabe, Michael G.; Yoong, Jaclyn; Everitt, Rachel; Mendis, Ruwani; Chua, Joyce; Pisasale, Maria; Le, Brian
title: A Multi-Centre COVID-19 Study Examining Symptoms and Medication Use in the Final Week of Life
date: 2022-05-26
journal: J Pain Symptom Manage
DOI: 10.1016/j.jpainsymman.2022.05.013
sha: 463c0d029a093bdb6f8b9652d31371d1363e31dd
doc_id: 938946
cord_uid: ik7qh2kl

CONTEXT: : Guidelines exist to direct end-of-life symptom management in COVID-19 patients. However, the real-world symptom patterns, and degree of concordance with guidelines on medication use, and palliative care involvement has received limited attention. OBJECTIVES: : To describe the evolution of COVID-19 symptoms, medication used to alleviate these, and degree of palliative care involvement in the final week of life. METHODS: : This retrospective study reviewed all COVID-19 inpatient deaths across five metropolitan hospitals in Australia from 1 January – 31 December 2020. Outcome measures were collected at day of death, and days 1, 2, 5, and 7 before death. These were COVID-19 symptom severity (measured by the Palliative Care Outcome Scale), and use of supportive pharmacological and non-pharmacological therapies. Palliative care referral timepoint was also collected. RESULTS: : Within the sample of 230 patients, commonest symptoms were breathlessness, agitation, pain, and respiratory secretions. On day of death, 79% (n=181) experienced at least one symptom, and 30% (n=68) experienced severe/extreme symptoms. The use of midazolam, glycopyrrolate, and infusions for symptom management occurred late, less frequently, and at lower doses than suggested in guidelines and other studies. Palliative care referrals were made late, at median 3 days before death (IQR 1-6 days), and for only half of people dying from COVID-19 (51%; n=118). CONCLUSION: : Symptoms peaked in final 3 days of life. Earlier use of infusional and breakthrough medications should be considered in anticipation of symptoms given high likelihood of dying in discomfort. Earlier palliative care referral for high-risk patients should be considered at hospital admission.

As of May 2022, there have been 6.24 million deaths worldwide due to COVID-19 (Coronavirus Disease 2019)(1). In Australia, the state of Victoria has been most heavily affected, accounting for 90% of Australia's COVID-19 deaths in 2020(1, 2). This death rate had been relatively low until October 2021, but has increased more than 5-fold in the past short months(1). With more transmissible variants and increasing prevalence of disease, this is likely to rise(1).

It is known that COVID-19 decedents commonly suffer from breathlessness, pain, and agitation, with concordant local and international guidelines to guide management (3) (4) (5) (6) (7) (8) . However, the real-world symptom patterns, and degree of concordance with guidelines on medication use, and palliative care involvement in Australia and overseas has received limited attention. This multi-site study aims to describe the evolution of COVID-19 symptoms, medication used to alleviate these, and degree of palliative care involvement in the final week of life amongst COVID-19 decedents in hospitals in Victoria, Australia in 2020. Given that in the past 24 months total COVID-19 deaths worldwide have increased by almost 20-fold(1), the likely ongoing rise in COVID-19 deaths mean there is benefit in the characterisation of these elements, with exigency for quality improvement in the management of COVID-19 deaths.

Design: This retrospective study reviewed all COVID-19 inpatient deaths across five metropolitan hospitals in Melbourne, Australia, expanding upon the outcomes of a single centre study (9) . Participants: The study cohort included patients of all ages who died from 1 January to 31 December 2020 due to COVID-19, with diagnosis determined by DRG (diagnosis-related group) coding identified from the patients' discharge summary performed post-death. Deaths not directly caused by COVID-19 were excluded.

Data collection: All daily clinical notes in patients' health records were interrogated and collected systematically by medical and palliative care teams across the 5 participating sites, which involved in total 10 hospital doctors and 3 research nurses. De-identified outcome data were extracted from the medical records of eligible cases using an electronic standardised case report form (REDCap, Vanderbilt University). A detailed data dictionary was available, with standardization and data quality checks completed by a senior palliative care consultant and research nurse for each site, and separately conducted centrally by a senior palliative care research consultant and senior research nurse. Data collected included:  Demographic and clinical characteristics, including the Australian-modified Karnofsky Performance Status (AKPS) (10) . Ventilated patients (n=13) were excluded from the analysis of morphine and midazolam use on the basis that it would not reflect usual dose titration against symptom intensity in this cohort. Patients from one centre (n=38) were excluded from analyses for palliative care involvement because by default they were seen by a senior doctor who was dual-trained in palliative care, rather than formally referred to the palliative care consult service.

A total of 230 COVID-19 deaths were recorded. Patient demographics and admission characteristics are summarised in Relative to symptom onset, patients were diagnosed with COVID-19 within 1 day (IQR 0-3), admitted within 2 days (IQR 0-5), and died 9 days later (IQR 4-16).

All patients had Goals of Care documented, completed a median of 6 days (IQR 3-12) prior to death. Most patients were identified as not for resuscitation (74%; n=170) at that time. Goals of Care were updated for 51% (n=117) of patients, and subsequently for another 18% (n=42) of patients, with very few remaining at full/limited resuscitation (6.5%;n=15, and 4.4%;n=10 respectively). The median number of days between final Goals of Care documentation and death was 3.

Severe/extreme symptoms doubled in final 3 days of life (30-31%;n=63-68) compared to days 5 (17%; n=30) and 7 (14%; n=19). This peaked at 1 day before death, where almost half (47%; n=32) had 2 or more severe/extreme symptoms. Most of these symptoms were breathlessness, agitation, pain, and respiratory secretions.

Of recorded symptoms at any severity, the prevalence of breathlessness and respiratory secretions peaked on day of death (64% (n=146) and 27% (n=63) respectively), whereas agitation and pain peaked on day before death (49% (n=109) and 38% (n=85) respectively) ( Table 2 ). Although patients were least symptomatic on day of death, 79% (n=181) still had at least one symptom.

Most patients who experienced the 4 commonest symptoms (breathlessness, agitation, pain, respiratory secretions) were not referred to palliative care until 1 day before death. Most patients with fever and cough were not referred to palliative care.

Breathlessness and respiratory secretions were the only symptoms that increased closer to death. On the day of death, the proportion of patients with each symptom was less in the palliative care cohort, except for breathlessness (64 vs 63%) and respiratory secretions (27% vs 27%), where the proportion was similar or equal across both groups.

Opioids were administered for the large majority of patients (Table 3) , with 44% (n=53) given at least 1 dose of opioid at 7 days before death, increasing to almost every patient (98%; n=213) on day of death (Figure 1 ). Median total opioid doses doubled (25mg to 57mg), and median breakthrough frequency tripled in this period.

Of non-ventilated patients, most who were prescribed a sedative received midazolam (94%; n=165). Midazolam use increased 11-fold in the in the final week (7% (n=9) to 76% (n=165)), with greatest use in the final 3 days of life. The mean daily dose and breakthrough frequency remained similar throughout (10mg; 1-2 breakthroughs/day).

Glycopyrrolate was the commonest antisecretory agent used; only 1 patient was prescribed hyoscine butylbromide instead. Its use increased daily to every patient experiencing secretions receiving glycopyrrolate on day of death. Figure 1 demonstrates the use of opioids, midazolam, and glycopyrrolate, relative to their respective symptoms.

This study is one of the first multisite studies to explore the evolution of symptoms and the medication management of COVID-19 deaths. In our cohort, the median age of decedents was 86 years, reflective of worldwide data on higher death rates with age (14) .

Breathlessness was the commonest observed symptom, matching reports from other centres (9, (15) (16) (17) . Although it is noted that breathlessness is ideally a patient-reported subjective measure, clinician assessment was utilised in our cohort of poorly communicative terminal patients. We observed that breathlessness increased closer to death (64% on day of death).

Opioid use increased closer to death, appearing to follow the trend of prevalence of breathlessness (rather than pain) at each day. It seems likely that opioid prescribing was instituted and escalated in response to worsening breathlessness. Nevertheless, despite the significant increases in opioids (by two-fold) and sedatives (by 11-fold) in the final week, breathlessness remained the most prevalent severe/extreme symptom observed on day of death (24%), meaning that in a quarter of patients, breathlessness did not appear to be relieved by those interventions administered, or required a change to a different intervention.

Similarly, more patients experienced respiratory secretions closer to death (27% on day of death). Severe/extreme secretions were experienced by 5% of the cohort. Secretions have been reported in 12%-47% of COVID-19 decedents (16, 17) , but interestingly, this is less common compared to reported prevalence in a cohort dying from non-COVID causes (17, 18) . Local and international guidelines encourage the use of antisecretory medications (4, 6, 8, 19) . A recent randomised controlled trial in non-covid palliative care patients have revealed that the prophylactic use of antisecretory agents for those patients at risk of secretions led to significantly less likelihood of developing secretions than a control group who received an as required approach (6% vs 61%) (20) . A large Swedish study found that complete relief from secretions was obtainable in a third of COVID-19 decedents, similar to the general dying cohort, and referenced the use of antisecretory medications in their guidelines (17) . However, our cohort saw a 60% increase in patients with secretions on the final day of life. Although the use of glycopyrrolate increased six-fold in the final week, not every patient with secretions received glycopyrrolate until the day of death. Up to 12% of patients received suctioning, although this is discouraged by guidelines as being ineffective as secretions are below the glottis, in addition to potentially being distressing. These data would suggest that for patients dying from COVID-19 the early introduction of antisecretory medications prophylactically should be adopted.

Our cohort was generally frail, identified to be not for resuscitation on admission, and were at risk of death from COVID-19, yet midazolam use was comparatively low. Not all patients suffering agitation received midazolam, and for many who did, this did not occur until the day before death. This is despite midazolam use being recommended as best practice in COVID-19 patients who are expected to die (4) (5) (6) 8) . This finding correlates with the literature, with a multi-centre study in the United Kingdom also reporting that only one-third of COVID-19 decedents received anticipatory medications for comfort (21) . A more vigilant and proactive approach to prescribing should be adopted. We support the suggestions of other authors (22) to consider starting an infusion early and in anticipation of likely symptoms that may arise in COVID-19 end-of-life care.

Furthermore, the dose of midazolam administered was largely static throughout the final 8 days of life. Regardless of whether it was administered by continuous infusion or by as needed bolus injection, the mean total daily dose was 10mg. It is likely that the median midazolam dose of 12.5mg on day of death was not adequate to optimally control agitation, since 40% were reported to have agitation and 10% had severe/extreme agitation on day of death. National Institute for Health and Care Excellence (NICE) guidelines(4) suggest a general minimum starting midazolam infusion dose of 10mg for agitation, and to titrate its dose to response, and National Health Service (NHS) guidelines suggest a daily dose of up to 60mg (5) . It is possible that lower doses were used due to our cohort being largely composed of elderly frail patients, however the data indicate that these doses were at the lower end of guideline recommendations, and remained inadequate. An infusion commenced earlier, perhaps in anticipation of symptoms or once symptoms arose, may have provided more time for appropriate dose escalation, and possibly reduced the prevalence and severity of agitation towards death.

The Australian National COVID-19 Clinical Evidence Taskforce(7) encourages early specialist palliative care involvement for COVID-19 patients who have pre-existing advanced progressive disease, such as that in our cohort. However, only 51% of our frail, high-risk cohort were referred to palliative care. These referrals occurred late (median 3 days before death), despite patients having been in hospital a median of 6 days prior. It was also generally less common for patients who experienced any symptom to be referred to palliative care until 1 day before death. On the day of death, the cohort known to palliative care was proportionally less symptomatic on most symptoms, providing further rationale for palliative care involvement earlier in the trajectory. Breathlessness and respiratory secretions -the only two symptoms which peaked on day of death -were similarly prevalent in both groups, and possibly reflects the nature of COVID-19. However, as previously highlighted, our sample had used relatively low doses of medications.

Final goals of care documentation were completed 3 days before death, and the doses of opioids, midazolam, and glycopyrrolate increased significantly in this time (Figure 1) , indicating a possible role of palliative care teams in facilitating goals of care discussions and symptom management. It is possible that earlier palliative care involvement may have resulted in earlier use of glycopyrrolate and midazolam in our cohort, and at higher doses, to manage the problematic respiratory secretions and agitation towards death which remained relatively prevalent in our cohort. Data suggests our international counterparts have been able to control symptoms in people dying of COVID-19 with greater success (17) , perhaps in part due to increased compliance with consensus guidelines and greater involvement of palliative care expertise. A recent scoping review(23) on inpatient COVID-19 deaths showed a large increase in palliative care referrals, whose role was similarly to guide goals of care and symptom management. Other authors have also supported the role of early palliative care in patients at high risk of dying from COVID-19 (8, 24) . Thus it is likely that earlier palliative care involvement in a specifically frail cohort likely to die from COVID-19 will be beneficial as well.

Study limitations: This study is limited by the retrospective design and metropolitan setting in one state in 2020; however these were also where most COVID-19 deaths occurred in Australia. We note the more recent spike in deaths has only occurred in the recent 4 months, where data has not matured yet but certainly warrants future exploration and research. A retrospective design was used as it was not possible to prospectively collect data given restrictions on non-clinical personnel attending hospitals. Being the state with the most COVID-19 cases and deaths, it was not reasonable to expect clinical staff to collect extra research data in the overwhelmed health system. As with other studies on critically ill and terminal patients, our data collection is limited to clinician observation, rather than patient-reported data; as such, this may be a reason symptoms such as nausea or sore throat were less apparent in our cohort of terminally ill patients. Although our cohort comprised of largely elderly and frail patients, most COVID-19 decedents remain in this category. As such our results remain translatable to the cohort of patients more likely to die from this illness.

This is one of the largest Australian studies reporting longitudinal patterns of symptom and medication use in the final week of life for patients dying from COVID-19. Symptoms were particularly troublesome in the final 3 days of life, with 79% decedents experiencing at least one symptom, and 30% experiencing severe/extreme symptoms on day of death. This may be in part due to the fact that the use of midazolam, glycopyrrolate, and infusions for symptom management occurred late, less frequently, and at relatively lower doses than suggested in many guidelines. Palliative care referrals also occurred late, and in only half of this high-risk population.

As the situation evolves, the current climate requires that patients are only admitted if they require hospital care, meaning these patients are likely to be admitted later, if at all. With hospital admissions occurring later in the illness trajectory, routine palliative care referral for this frail cohort should be considered at admission. Low dose medication infusion for symptom management should be considered in anticipation when a patient is expected to die from COVID-19, given the high likelihood of experiencing troublesome and severe symptoms. Midazolam and glycopyrrolate could be used more frequently and at higher doses to reflect need, and to reduce our comparatively higher symptom burden compared to other reports. Future research may address the impact of palliative care involvement and on improving adherence to guidelines on symptom control in this cohort.

Disclosures: The authors declare no conflicts of interest. 

Days from symptom onset to diagnosis 1 (0-3)

Days from symptom onset to admission 2 (0-5)

Days from symptom onset to death 11 (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) Days from Palliative Care referral to death 3 (1-6)

Days from first goals of care to death 6 (3-12)

Days from last goals of care to death 3 (1-6) *Patients from one centre (n=38) were excluded on basis that the senior doctor in charge was dualtrained in palliative care 

World Health Organisation. WHO Coronavirus Disease (COVID-19) Dashboard

World Health Organisation

An interactive web-based dashboard to track COVID-19 in real time

World Health Organisation. Living guidance for clinical management of COVID-19

Managing COVID-19 symptoms (including at the end of life) in the community: summary of NICE guidelines

Specialty guides for patient management during the coronavirus pandemic. Clinical guide for the management of palliative care in hospital during the coronavirus pandemic

Further Symptom Management in COVID-19: Treatment Approaches and Alternative Routes. Version 1.1. Canberra2020. 7. National COVID-19 Clinical Evidence Taskforce. Management Of People With Covid-19 Who Are Receiving Palliative Care

Symptom Management and Supportive Care of Serious COVID-19 Patients and their Families in India

COVID-19 end-of-life care: symptoms and supportive therapy use in an Australian hospital

The Australia-modified Karnofsky Performance Status (AKPS) scale: a revised scale for contemporary palliative care clinical practice

A new method of classifying prognostic comorbidity in longitudinal studies: development and validation

Faculty of Pain Medicine. Opioid Dose Equivalence: Calculation of oral Morphine Equivalent Daily Dose (oMEDD): Australian and New Zealand College of Anaesthetists

Agespecific mortality and immunity patterns of SARS-CoV-2

Symptom Management, and Outcomes of 101 Patients With COVID-19 Referred for Hospital Palliative Care

An audit of end-of-life symptom control in patients with corona virus disease 2019 (COVID-19) dying in a hospital in the United Kingdom

Symptoms, symptom relief and support in COVID-19 patients dying in hospitals during the first pandemic wave

Prevalence, impact, and treatment of death rattle: a systematic review

Benefits of interventions for respiratory secretion management in adult palliative care patients-a systematic review

Hyoscine Butylbromide for the Management of Death Rattle: Sooner Rather Than Later

Death from COVID-19: management of breathlessness: a retrospective multicentre study

Palliative care for patients with severe covid-19

Hospital-Based Palliative and End-of-Life Care in the COVID-19 Pandemic: A Scoping Review

Response and role of palliative care during the COVID-19 pandemic: A national telephone survey of hospices in Italy

Acknowledgements: We acknowledge the Palliative Care team at each site, and junior medical staff at Northern Health for data collection.Funding: This work was supported by North and West Metropolitan Region Palliative Care Consortium.